Prognostic Significance of Long Non Coding RNA ANRIL and SNHG14 in Acute Myeloid Leukemia.

BACKGROUND

Long non-coding RNAs (lnRNAs) play a pivotal role in various malignancies including AML. Therefore, we decided to study both lnRNA ANRIL and lnRNA SNHG14 gene expressions in patients with AML to better understand their role in AML risk development, clinical presentation, and prognosis.

METHODS

The current prospective study included two hundred participants, 100 AML patients and 100 control subjects. Bone marrow analysis was made to all patients, in addition to gene expression molecular testing of both lnRNA ANRIL and lnRNA SNHG14.

RESULTS

Both lnRNA SNHG14 and lnRNA ANRIL showed high expression levels in AML bone marrow samples compared to non-AML subjects and were remarkably associated with lower Complete Remission (OR: 3.449, 95% CI: 1.324-8.985, p=0.011 for ANRIL and OR: 3.955, 95% CI: 1.510-10.356, p=0.005 for SNHG14), Relapse Free Survival (HR=3.504, 95%CI: 1.662-7.387, p=0.001 for ANRIL and HR=4.094, 95%CI: 1.849-9.067, p=0.001 for SNHG14) and Overall Survival (HR=3.353, 95%CI: 1.434-7.839, p=0.005 for ANRIL and HR=3.094, 95%CI: 1.277-7.494, p=0.012 for SNHG14), favouring poor prognostic significance in AML.

CONCLUSION

This suggests that both lnRNA ANRIL and lnRNA SNHG14 could be used in the future as prognostic biomarkers to help in treatment decisions and follow up of AML patients.